drugset / Trial / NCT02421042

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

NCT02421042

Phase 1 Completed 14 enrolled Eisai Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open-label, non-randomized, single-dose, sequential-cohort study in subjects with varying degrees of hepatic impairment, classified according to the Child-Pugh system, who will be matched with normal healthy subjects as controls.

Timeline

Start
2011-06
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 5 mg Oral
Subject Lenvatinib Small molecule 10 mg Oral

Indications

No indication recorded.